Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1139 in Moderate-to-Severe Active Ulcerative Colitis
NCT07232576Phase 2Active, not recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2025
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1139 in ulcerative colitis (UC), sponsored by Hengrui Therapeutics. Started Dec 2025; status: active, not recruiting.
02
Drugs
SHR-1139
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07232576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232576.